Navigation Links
DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
Date:10/26/2013

Dallas, TX (PRWEB) October 26, 2013

The prescription drug resource center DrugRisk.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recently published study identified the drug as the most often reported for serious side effects like internal bleeding*.

The news comes on the same day as a federal court disclosed the number of lawsuits alleging internal bleeding injuries has again grown**.

The DrugRisk center is a free resource for those taking popular prescription drugs. By providing the latest product recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding.

The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin***. Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from warfarin bleeding****. A study this year from the Netherlands also suggested patients taking blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding*****.

Now. DrugRisk has learned that the latest study from the Institute for Safe Medication Practices found Pradaxa ranked highest for number of complaints to the FDA last year, with 683 reports of bleeding*.

A growing number of patients have also filed a Pradaxa lawsuit alleging internal bleeding, leading to the consolidation of cases in a special federal multidistrict litigation court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

DrugRisk has added the latest court records from the Judicial Panel on Multidistrict Litigation, which show the number of cases filed has increased from 1,470 on September 11th to 1,643 on October 17, a rise of nearly 12% in less than a month**.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*Institute for Safe Medication Practices, 10/17/13; ismp.org/quarterwatch/pdfs/2012Q4.pdf
**Judicial Panel on Multidistrict Litigation, 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext

Read the full story at http://www.prweb.com/releases/2013-pradaxa/gastrointestinal-bleeding/prweb11271909.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Alerts of New Rise In Mirena Lawsuits Alleging Uterine Damage
2. DrugRisk Updates with Latest Case Numbers Since Januvia Lawsuits Sent to MDL Court
3. DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
4. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
5. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
6. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
7. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
8. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
9. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
10. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
11. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... A new ... for Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, ... Montague, a 2003 graduate of FHU and the creator of GO! Camp, has been ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... staff helped give free oral screenings to 150 children in kindergarten through third ... The College of Dental Medicine joined Chinese American Dental Society of Southern California ...
(Date:2/10/2016)... FLA (PRWEB) , ... February 09, 2016 , ... ... team at Clevens Face and Body Specialists are delighted to welcome a new ... ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 09, 2016 , ... ... surgeons are witnessing a dramatic increase in the number of patients under the age ... reflects what they are seeing in their offices, and may indicate an overall shift ...
(Date:2/10/2016)... ... 2016 , ... Traumatic Brian Injury is often in the ... of many possible sources: sports, car accidents, falls, work accidents, combat and other ... Solutions for the Complexities of Concussions is designed for physical and occupational ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... HALLANDALE, Fla. , Feb. 9, 2016  Until ... sagging were surgery or liposuction. Thankfully, the FDA approved ... freezing them to death. Coolsculpting was originally approved in ... to the thighs and now the chin. With this ... Wellness Center can use a smaller applicator, the CoolMini, ...
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/10/2016)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... the clinical studies being conducted under the Company,s ... the issuance of the Company,s February 8, 2016, ... by the U.S. Food and Drug Administration (FDA) ... oral communication from the FDA followed by a ...
Breaking Medicine Technology: